Aura Biosciences (AURA) Competitors $6.40 -0.37 (-5.47%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.40 0.00 (0.00%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. GPCR, CVAC, CALT, AUPH, BGM, NAGE, AMPH, DYN, ABCL, and PAHCShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals BGM Group Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health Aura Biosciences (NASDAQ:AURA) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Is AURA or GPCR more profitable? Structure Therapeutics' return on equity of -16.35% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -58.63% -49.74% Structure Therapeutics N/A -16.35%-15.71% Which has stronger valuation and earnings, AURA or GPCR? Structure Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.90-3.37Structure TherapeuticsN/AN/A-$122.53M-$0.87-21.85 Do insiders and institutionals hold more shares of AURA or GPCR? 96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer AURA or GPCR? In the previous week, Structure Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.87 beat Structure Therapeutics' score of 0.85 indicating that Aura Biosciences is being referred to more favorably in the media. Company Overall Sentiment Aura Biosciences Very Positive Structure Therapeutics Positive Do analysts rate AURA or GPCR? Aura Biosciences currently has a consensus price target of $22.00, suggesting a potential upside of 243.75%. Structure Therapeutics has a consensus price target of $76.17, suggesting a potential upside of 300.67%. Given Structure Therapeutics' higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, AURA or GPCR? Aura Biosciences has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.87, indicating that its stock price is 287% less volatile than the S&P 500. SummaryAura Biosciences and Structure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$340.32M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-3.3720.5827.9620.25Price / SalesN/A292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book2.117.638.045.49Net Income-$86.92M-$55.05M$3.18B$250.27M7 Day Performance-2.88%8.54%3.67%4.80%1 Month Performance-4.05%5.51%4.09%7.68%1 Year Performance-25.23%2.03%29.58%16.36% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences2.583 of 5 stars$6.40-5.5%$22.00+243.8%-22.7%$340.32MN/A-3.3750GPCRStructure Therapeutics2.6129 of 5 stars$20.74-1.6%$76.17+267.2%-55.5%$1.21BN/A-23.84136CVACCureVac4.6825 of 5 stars$5.43+0.9%$6.83+25.8%+67.0%$1.21B$579.18M5.90880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.0457 of 5 stars$8.47-2.0%$11.50+35.8%+50.2%$1.17B$235.13M30.25300Positive NewsBGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298NAGENiagen Bioscience1.3362 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.12B$99.60M84.76120AMPHAmphastar Pharmaceuticals4.3237 of 5 stars$22.96-0.5%$32.33+40.8%-44.7%$1.09B$731.97M8.322,028DYNDyne Therapeutics3.4216 of 5 stars$9.52-0.5%$41.13+332.0%-79.4%$1.09BN/A-2.65100Analyst ForecastABCLAbCellera Biologics2.2695 of 5 stars$3.43-5.0%$8.33+143.0%+28.1%$1.08B$28.83M-6.12500Analyst RevisionHigh Trading VolumePAHCPhibro Animal Health4.0515 of 5 stars$25.54-0.5%$21.80-14.6%+76.0%$1.04B$1.02B32.741,940Gap Up Related Companies and Tools Related Companies Structure Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors BGM Group Competitors Niagen Bioscience Competitors Amphastar Pharmaceuticals Competitors Dyne Therapeutics Competitors AbCellera Biologics Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
